Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1952 1
1967 1
1969 2
1970 2
1971 2
1973 1
1975 5
1976 1
1977 5
1978 1
1979 2
1980 4
1981 10
1982 13
1983 19
1984 38
1985 30
1986 32
1987 35
1988 35
1989 33
1990 29
1991 41
1992 46
1993 50
1994 49
1995 31
1996 50
1997 31
1998 36
1999 40
2000 53
2001 68
2002 59
2003 79
2004 102
2005 113
2006 120
2007 107
2008 130
2009 166
2010 147
2011 150
2012 153
2013 166
2014 188
2015 208
2016 173
2017 213
2018 210
2019 214
2020 208
2021 253
2022 214
2023 178
2024 225
2025 239
2026 84

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,285 results

Results by year

Filters applied: . Clear all
Page 1
CD19 CAR T-Cell Therapy in Autoimmune Disease - A Case Series with Follow-up.
Müller F, Taubmann J, Bucci L, Wilhelm A, Bergmann C, Völkl S, Aigner M, Rothe T, Minopoulou I, Tur C, Knitza J, Kharboutli S, Kretschmann S, Vasova I, Spoerl S, Reimann H, Munoz L, Gerlach RG, Schäfer S, Grieshaber-Bouyer R, Korganow AS, Farge-Bancel D, Mougiakakos D, Bozec A, Winkler T, Krönke G, Mackensen A, Schett G. Müller F, et al. N Engl J Med. 2024 Feb 22;390(8):687-700. doi: 10.1056/NEJMoa2308917. N Engl J Med. 2024. PMID: 38381673
BACKGROUND: Treatment for autoimmune diseases such as systemic lupus erythematosus (SLE), idiopathic inflammatory myositis, and systemic sclerosis often involves long-term immune suppression. ...CONCLUSIONS: In this case series, CD19 CAR T-cell transfer appeared to …
BACKGROUND: Treatment for autoimmune diseases such as systemic lupus erythematosus (SLE), idiopathic inflammatory myositis, an …
Chimeric antigen receptor T cell therapy for autoimmune disease.
Chung JB, Brudno JN, Borie D, Kochenderfer JN. Chung JB, et al. Nat Rev Immunol. 2024 Nov;24(11):830-845. doi: 10.1038/s41577-024-01035-3. Epub 2024 Jun 3. Nat Rev Immunol. 2024. PMID: 38831163 Free PMC article. Review.
This success inspired the development of CAR T cells to selectively deplete or modulate the aberrant immune responses that underlie autoimmune disease. Promising results are emerging from clinical trials of CAR T cells targeting the B cell protein CD19 in patients w …
This success inspired the development of CAR T cells to selectively deplete or modulate the aberrant immune responses that underlie autoi …
Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2).
Charles P, Terrier B, Perrodeau É, Cohen P, Faguer S, Huart A, Hamidou M, Agard C, Bonnotte B, Samson M, Karras A, Jourde-Chiche N, Lifermann F, Gobert P, Hanrotel-Saliou C, Godmer P, Martin-Silva N, Pugnet G, Matignon M, Aumaitre O, Viallard JF, Maurier F, Meaux-Ruault N, Rivière S, Sibilia J, Puéchal X, Ravaud P, Mouthon L, Guillevin L; French Vasculitis Study Group. Charles P, et al. Ann Rheum Dis. 2018 Aug;77(8):1143-1149. doi: 10.1136/annrheumdis-2017-212878. Epub 2018 Apr 25. Ann Rheum Dis. 2018. PMID: 29695500 Clinical Trial.
Controls received a fixed 500 mg rituximab infusion on days 0 and 14 postrandomisation, then 6, 12 and 18 months after the first infusion. ...At month 28, 21 patients had suffered 22 relapses: 14/81 (17.3%) in 13 tailored-infusion recipients and 8/81 (9.9%) i …
Controls received a fixed 500 mg rituximab infusion on days 0 and 14 postrandomisation, then 6, 12 and 18 months after the first i …
CD19 CAR T-Cell Therapy for Autoimmune Hemolytic Anemia.
Li R, Pan H, Zhang L, Ma J, Li W, Gao Z, Fang L, Tian L, Shen Y, Yang F, Zhao J, Nie N, Li J, Wang W, Pan X, Lian Y, Li X, Peng G, Li L, Yu X, Xu C, Liu Y, Kuang Z, Huang J, Zhao X, Ge M, Liu L, Chen S, Feng Y, Chang AH, Deng B, Dai M, Huang L, Lv L, Zheng Y, Luo Y, Xiong H, Shi J. Li R, et al. N Engl J Med. 2026 Jan 15;394(3):253-267. doi: 10.1056/NEJMoa2509820. N Engl J Med. 2026. PMID: 41534043 Clinical Trial.
BACKGROUND: In patients with autoimmune hemolytic anemia (AIHA), the risk of relapse is high owing to persistent autoreactive B-cell activity. Multirefractory AIHA is a more advanced stage of disease that is defined by a lack of response to at least three lines of …
BACKGROUND: In patients with autoimmune hemolytic anemia (AIHA), the risk of relapse is high owing to persistent autoreactive B-cell …
Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans.
Ulrichts P, Guglietta A, Dreier T, van Bragt T, Hanssens V, Hofman E, Vankerckhoven B, Verheesen P, Ongenae N, Lykhopiy V, Enriquez FJ, Cho J, Ober RJ, Ward ES, de Haard H, Leupin N. Ulrichts P, et al. J Clin Invest. 2018 Oct 1;128(10):4372-4386. doi: 10.1172/JCI97911. Epub 2018 Jul 24. J Clin Invest. 2018. PMID: 30040076 Free PMC article. Clinical Trial.
BACKGROUND: Intravenous Ig (IVIg), plasma exchange, and immunoadsorption are frequently used in the management of severe autoimmune diseases mediated by pathogenic IgG autoantibodies. These approaches modulating IgG levels can, however, be associated with some sever …
BACKGROUND: Intravenous Ig (IVIg), plasma exchange, and immunoadsorption are frequently used in the management of severe autoimmune …
CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis.
Fischbach F, Richter J, Pfeffer LK, Fehse B, Berger SC, Reinhardt S, Kuhle J, Badbaran A, Rathje K, Gagelmann N, Borie D, Seibel J, Ayuk F, Friese MA, Heesen C, Kröger N. Fischbach F, et al. Med. 2024 Jun 14;5(6):550-558.e2. doi: 10.1016/j.medj.2024.03.002. Epub 2024 Mar 29. Med. 2024. PMID: 38554710 Free article.
Although inflammatory activity can be prevented by immunomodulatory therapies during early disease, such therapies typically fail to halt disease progression. ...Successful use of CD19 CAR-T cells in rheumatic diseases like systemic lupus erythe …
Although inflammatory activity can be prevented by immunomodulatory therapies during early disease, such therapies typi …
Single-cell analysis of anti-BCMA CAR T cell therapy in patients with central nervous system autoimmunity.
Qin C, Zhang M, Mou DP, Zhou LQ, Dong MH, Huang L, Wang W, Cai SB, You YF, Shang K, Xiao J, Wang D, Li CR, Hao Y, Heming M, Wu LJ, Meyer Zu Hörste G, Dong C, Bu BT, Tian DS, Wang W. Qin C, et al. Sci Immunol. 2024 May 10;9(95):eadj9730. doi: 10.1126/sciimmunol.adj9730. Epub 2024 May 10. Sci Immunol. 2024. PMID: 38728414
Chimeric antigen receptor (CAR) T cell immunotherapy for the treatment of neurological autoimmune diseases is promising, but CAR T cell kinetics and immune alterations after treatment are poorly understood. ...Thus, we provide mechanistic insights into CAR T cell fu …
Chimeric antigen receptor (CAR) T cell immunotherapy for the treatment of neurological autoimmune diseases is promising, but C …
Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities.
Bittner B, Richter W, Schmidt J. Bittner B, et al. BioDrugs. 2018 Oct;32(5):425-440. doi: 10.1007/s40259-018-0295-0. BioDrugs. 2018. PMID: 30043229 Free PMC article. Review.
We focus on biotherapeutics in rheumatoid arthritis (RA), immunoglobulin-replacement therapy in primary immunodeficiency (PI), beta interferons in multiple sclerosis (MS), and monoclonal antibodies (mAbs) in oncology. ...Beside concerns around the safety of biotherapeutics …
We focus on biotherapeutics in rheumatoid arthritis (RA), immunoglobulin-replacement therapy in primary immunodeficiency (PI), beta i …
Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with autoimmune disease: an observational study.
Hagen M, Müller F, Wirsching A, Kharboutli S, Spoerl S, Düsing C, Krickau T, Metzler M, Völkl S, Aigner M, Kretschmann S, Vasova I, Saake M, Schliep S, Kubacki T, Hunzelmann N, Bucci L, Taubmann J, Bergmann C, Györfi AH, Dietrich S, Distler JHW, Grieshaber-Bouyer R, Mackensen A, Schett G. Hagen M, et al. Lancet Rheumatol. 2025 Jun;7(6):e424-e433. doi: 10.1016/S2665-9913(25)00091-8. Epub 2025 Apr 30. Lancet Rheumatol. 2025. PMID: 40318690 Free article.
Data regarding side-effects are mostly generated from patients with malignancies, but little is known about autoimmune disease-specific adverse events. This study aimed to describe autoimmune disease-specific adverse events that occur with CAR T-cell …
Data regarding side-effects are mostly generated from patients with malignancies, but little is known about autoimmune disease …
Treatment of concomitant myasthenia gravis and Lambert-Eaton myasthenic syndrome with autologous CD19-targeted CAR T cells.
Motte J, Sgodzai M, Schneider-Gold C, Steckel N, Mika T, Hegelmaier T, Borie D, Haghikia A, Mougiakakos D, Schroers R, Gold R. Motte J, et al. Neuron. 2024 Jun 5;112(11):1757-1763.e2. doi: 10.1016/j.neuron.2024.04.014. Epub 2024 May 1. Neuron. 2024. PMID: 38697115 Free article.
Two women diagnosed with concomitant MG/LEMS experienced severe, increasing disease activity despite multiple immunotherapies. Anti-CD19 chimeric antigen receptor (CAR) T cells have shown promise for treating autoimmune diseases. ...Within 2 months, both pati …
Two women diagnosed with concomitant MG/LEMS experienced severe, increasing disease activity despite multiple immunotherapies. Anti-C …
4,285 results